Ost-müük Phio Pharmaceuticals Corp. - PHIO CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | 0.08 | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | 3.3 |
| Avatud* | 3.26 |
| Aastane muutus* | 386.57% |
| Päeva ulatus* | 3.21 - 3.3 |
| 52 nädala ulatus | 3.11-12.27 |
| Keskmine maht (10 päeva) | 308.32K |
| Keskmine maht (3 kuud) | 12.13M |
| Turukapitalisatsioon | 5.03M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 1.81M |
| Tulu | N/A |
| EPS | -10.92 |
| Dividendid (% kasumist) | N/A |
| Beeta | 1.51 |
| Järgmine tuluaruande kuupäev | Aug 9, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 3.27 | -0.01 | -0.30% | 3.28 | 3.34 | 3.20 |
| Jun 1, 2023 | 3.30 | -0.13 | -3.79% | 3.43 | 3.43 | 3.18 |
| May 31, 2023 | 3.37 | -0.10 | -2.88% | 3.47 | 3.50 | 3.31 |
| May 30, 2023 | 3.93 | 0.06 | 1.55% | 3.87 | 4.06 | 3.85 |
| May 26, 2023 | 3.95 | 0.28 | 7.63% | 3.67 | 4.00 | 3.57 |
| May 25, 2023 | 3.73 | -0.16 | -4.11% | 3.89 | 3.92 | 3.67 |
| May 24, 2023 | 4.15 | -0.82 | -16.50% | 4.97 | 5.22 | 3.98 |
| May 23, 2023 | 4.22 | 0.05 | 1.20% | 4.17 | 4.37 | 4.15 |
| May 22, 2023 | 4.18 | 0.04 | 0.97% | 4.14 | 4.37 | 4.14 |
| May 19, 2023 | 4.29 | -0.04 | -0.92% | 4.33 | 4.73 | 4.24 |
| May 18, 2023 | 4.89 | 1.51 | 44.67% | 3.38 | 6.81 | 3.37 |
| May 17, 2023 | 3.73 | -0.10 | -2.61% | 3.83 | 4.14 | 3.71 |
| May 16, 2023 | 4.02 | -0.14 | -3.37% | 4.16 | 4.85 | 3.69 |
| May 15, 2023 | 3.33 | 0.02 | 0.60% | 3.31 | 3.40 | 3.31 |
| May 12, 2023 | 3.47 | -0.23 | -6.22% | 3.70 | 3.71 | 3.45 |
| May 11, 2023 | 3.79 | -0.25 | -6.19% | 4.04 | 4.04 | 3.76 |
| May 10, 2023 | 3.94 | -0.02 | -0.51% | 3.96 | 4.05 | 3.82 |
| May 9, 2023 | 4.01 | 0.04 | 1.01% | 3.97 | 4.03 | 3.84 |
| May 8, 2023 | 3.89 | -0.18 | -4.42% | 4.07 | 4.11 | 3.88 |
| May 5, 2023 | 3.89 | 0.08 | 2.10% | 3.81 | 3.94 | 3.77 |
Phio Pharmaceuticals Corp. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| Wednesday, August 9, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q2 2023 Phio Pharmaceuticals Corp Earnings Release Q2 2023 Phio Pharmaceuticals Corp Earnings ReleaseForecast -Previous - |
| Kellaaeg (UTC) (UTC) 18:00 | Riik US
| Sündmus Phio Pharmaceuticals Corp Annual Shareholders Meeting Phio Pharmaceuticals Corp Annual Shareholders MeetingForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Kellaaeg (UTC) (UTC) 10:59 | Riik US
| Sündmus Q3 2023 Phio Pharmaceuticals Corp Earnings Release Q3 2023 Phio Pharmaceuticals Corp Earnings ReleaseForecast -Previous - |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0.021 | 0.138 |
| Tulu | 0 | 0.021 | 0.138 | ||
| Kogu tegevuskulu | 11.462 | 13.278 | 8.793 | 9.008 | 7.502 |
| Müük/Üldine/admin kulud, kokku | 4.45 | 4.625 | 4.362 | 4.708 | 3.176 |
| Uuringud ja arendus | 7.012 | 8.886 | 4.431 | 4.3 | 4.326 |
| Tulud majandustegevusest | -11.462 | -13.278 | -8.793 | -8.987 | -7.364 |
| Intressitulud (kulu), muud tulud, neto | -0.009 | ||||
| Muud, neto | -0.018 | -0.001 | 0.079 | 0.004 | |
| Netotulu enne makse | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Netotulu pärast makse | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Netotulu enne erikulusid | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Netotulu | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Total Adjustments to Net Income | |||||
| Arvestatav tulu, v a erikulud | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Arvestatav tulu, koos erikuludega | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Jaotamisele kuuluv netotulu | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Keskmine jaotamisele kuuluv aktsia kohta | 1.13657 | 1.06919 | 0.38226 | 0.0384 | 0.01067 |
| Jaotatav EPS, v a erakorralised kulud | -10.1006 | -12.4271 | -23.0051 | -231.984 | -689.565 |
| Jaotamisele kuuluv normaal-EPS | -10.1006 | -12.6451 | -23.0051 | -231.984 | -689.565 |
| Ootamatud kulutused (tulu) | -0.233 | 0 | |||
| Erakorralised kulud kokku |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 3.602 | 2.73 | 3.571 | 2.521 | 2.64 |
| Müük/Üldine/admin kulud, kokku | 1.468 | 1.116 | 1.063 | 1.217 | 1.054 |
| Uuringud ja arendus | 2.134 | 1.614 | 2.508 | 1.304 | 1.586 |
| Ootamatud kulutused (tulu) | |||||
| Tulud majandustegevusest | -3.602 | -2.73 | -3.571 | -2.521 | -2.64 |
| Intressitulud (kulu), muud tulud, neto | |||||
| Netotulu enne makse | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Netotulu pärast makse | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Netotulu enne erikulusid | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Netotulu | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Arvestatav tulu, v a erikulud | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Arvestatav tulu, koos erikuludega | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Jaotamisele kuuluv netotulu | -3.602 | -2.731 | -3.576 | -2.531 | -2.642 |
| Keskmine jaotamisele kuuluv aktsia kohta | 1.14221 | 1.13903 | 1.13853 | 1.13818 | 1.1303 |
| Jaotatav EPS, v a erakorralised kulud | -3.15353 | -2.39765 | -3.1409 | -2.22372 | -2.33743 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -3.15353 | -2.39765 | -3.1409 | -2.22372 | -2.33743 |
| Muud, neto | 0 | -0.001 | -0.005 | -0.01 | -0.002 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 12.446 | 24.727 | 15.164 | 7.3 | 15.15 |
| Raha ja lühiajalised investeeringud | 11.781 | 24.057 | 14.244 | 6.934 | 14.879 |
| Raha ja ekvivalendid | 11.781 | 24.057 | 14.244 | 6.934 | 14.879 |
| Prepaid Expenses | 0.615 | 0.62 | 0.87 | 0.316 | 0.221 |
| Other Current Assets, Total | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Total Assets | 12.814 | 25.17 | 15.739 | 8.039 | 15.322 |
| Property/Plant/Equipment, Total - Net | 0.344 | 0.416 | 0.557 | 0.721 | 0.172 |
| Property/Plant/Equipment, Total - Gross | 1.519 | ||||
| Accumulated Depreciation, Total | -1.175 | ||||
| Note Receivable - Long Term | |||||
| Other Long Term Assets, Total | 0.024 | 0.027 | 0.018 | 0.018 | 0 |
| Total Current Liabilities | 1.939 | 3.068 | 2.196 | 1.88 | 1.744 |
| Accounts Payable | 0.779 | 0.283 | 0.728 | 0.809 | 0.55 |
| Accrued Expenses | 1.16 | 2.785 | 1.468 | 1.071 | 1.194 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.97389 | 3.238 | 2.722 | 2.291 | 1.744 |
| Total Long Term Debt | 0 | 0 | 0.231 | 0 | 0 |
| Total Equity | 10.8401 | 21.932 | 13.017 | 5.748 | 13.578 |
| Preferred Stock - Non Redeemable, Net | 0.002 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00011 | 0.001 | 0.001 | 0.001 | 0.002 |
| Additional Paid-In Capital | 139.218 | 138.831 | 116.629 | 100.566 | 99.487 |
| Retained Earnings (Accumulated Deficit) | -128.38 | -116.9 | -103.613 | -94.819 | -85.911 |
| Total Liabilities & Shareholders’ Equity | 12.814 | 25.17 | 15.739 | 8.039 | 15.322 |
| Total Common Shares Outstanding | 1.13902 | 1.12787 | 0.48173 | 0.05578 | 0.02854 |
| Total Preferred Shares Outstanding | |||||
| Other Liabilities, Total | 0.03489 | 0.17 | 0.295 | 0.411 | |
| Long Term Debt | 0 | 0.231 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 9.404 | 12.446 | 15.377 | 19.688 | 21.667 |
| Raha ja lühiajalised investeeringud | 9.035 | 11.781 | 14.484 | 18.02 | 20.459 |
| Raha ja ekvivalendid | 9.035 | 11.781 | 14.484 | 18.02 | 20.459 |
| Prepaid Expenses | 0.319 | 0.615 | 0.843 | 1.618 | 1.158 |
| Other Current Assets, Total | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Total Assets | 9.707 | 12.814 | 15.791 | 20.144 | 22.162 |
| Property/Plant/Equipment, Total - Net | 0.297 | 0.344 | 0.39 | 0.429 | 0.468 |
| Other Long Term Assets, Total | 0.006 | 0.024 | 0.024 | 0.027 | 0.027 |
| Total Current Liabilities | 2.396 | 1.939 | 2.194 | 3.037 | 2.573 |
| Accounts Payable | 0.902 | 0.779 | 0.543 | 1.148 | 0.329 |
| Accrued Expenses | 1.494 | 1.16 | 1.651 | 1.889 | 2.244 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.396 | 1.97389 | 2.264 | 3.141 | 2.711 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Other Liabilities, Total | 0 | 0.03489 | 0.07 | 0.104 | 0.138 |
| Total Equity | 7.311 | 10.8401 | 13.527 | 17.003 | 19.451 |
| Preferred Stock - Non Redeemable, Net | 0 | 0.002 | 0 | 0 | 0 |
| Common Stock | 0 | 0.00011 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 139.293 | 139.218 | 139.175 | 139.075 | 138.992 |
| Retained Earnings (Accumulated Deficit) | -131.982 | -128.38 | -125.649 | -122.073 | -119.542 |
| Total Liabilities & Shareholders’ Equity | 9.707 | 12.814 | 15.791 | 20.144 | 22.162 |
| Total Common Shares Outstanding | 1.15058 | 1.13902 | 1.13895 | 1.13818 | 1.13818 |
- Aastas
- Kvartalis
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netotulu/algväärtus | -11.48 | -13.287 | -8.794 | -8.908 | -7.36 |
| Raha majandustegevusest | -12.129 | -11.858 | -8.802 | -8.645 | -7.52 |
| Raha majandustegevusest | 0.071 | 0.075 | 0.072 | 0.067 | 0.081 |
| Mittelikviidsed varad | 0.536 | 0.364 | 0.247 | 0.409 | 0.282 |
| Muutused tööjõus | -1.256 | 0.99 | -0.327 | -0.213 | -0.523 |
| Tulu investeeringutelt | -0.121 | -0.051 | -0.019 | -0.072 | -0.005 |
| Kapitalikulutused | -0.121 | -0.051 | -0.019 | -0.072 | -0.005 |
| Muud rahavood investeeringutelt, kokku | 0 | ||||
| Rahavood investeeringutelt | -0.026 | 21.722 | 16.131 | 0.772 | 18.823 |
| Aktsiate emiteerimine (tagasiost), neto | 0 | 21.723 | 15.944 | 0.781 | 18.823 |
| Rahaline kogumuutus | -12.276 | 9.813 | 7.31 | -7.945 | 11.298 |
| Deferred Taxes | 0 | ||||
| Makstud intressid | 0.008 | 0.006 | 0 | 0.003 | |
| Rahavoogudesse investeerimine | -0.026 | -0.001 | -0.017 | -0.003 | |
| Laenu väljastamine (kustutamine), neto | 0 | 0.204 | -0.006 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.602 | -11.48 | -8.749 | -5.173 | -2.642 |
| Cash From Operating Activities | -2.708 | -12.129 | -9.424 | -5.898 | -3.469 |
| Cash From Operating Activities | 0.016 | 0.071 | 0.056 | 0.041 | 0.022 |
| Non-Cash Items | 0.142 | 0.536 | 0.463 | 0.329 | 0.216 |
| Changes in Working Capital | 0.736 | -1.256 | -1.194 | -1.095 | -1.065 |
| Cash From Investing Activities | 0 | -0.121 | -0.121 | -0.114 | -0.104 |
| Capital Expenditures | 0 | -0.121 | -0.121 | -0.114 | -0.104 |
| Cash From Financing Activities | -0.038 | -0.026 | -0.028 | -0.025 | -0.025 |
| Financing Cash Flow Items | -0.036 | -0.026 | -0.028 | -0.025 | -0.025 |
| Issuance (Retirement) of Stock, Net | -0.002 | 0 | 0 | 0 | 0 |
| Net Change in Cash | -2.746 | -12.276 | -9.573 | -6.037 | -3.598 |
| Issuance (Retirement) of Debt, Net | |||||
| Cash Interest Paid |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Phio Pharmaceuticals Corp. Company profile
Ettevõttest Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. on biotehnoloogiaettevõte. Ettevõte keskendub immuun-onkoloogiliste ravimite väljatöötamisele, mis põhinevad tema isetoimetaval ribonukleiinhappe liidesel (RNAi) INTASYL terapeutilisel platvormil. Ettevõte on välja töötanud oma INTASYL-tehnoloogial põhineva tooteplatvormi, mis võimaldab adoptiivse rakuteraapia (ACT) rakkude ja kasvaja mikrokeskkonna (TME) selektiivset, geneetiliselt muundamata programmeerimist, mille tulemusena väheneb immuunsüsteemi pärssimine ja paraneb immunoteraapia. Peamine tootekandidaat PH-762 on INTASYLi ühend, mis on suunatud kontrollpunktvalgule PD-1, mis toimib teatud tüüpi lülitina, mis takistab T-rakkude ründamist teatud rakkude, näiteks vähirakkude vastu organismis. Teine tootekandidaat PH-894 on INTASYLi ühend, mis on suunatud BRD4-le, mis on rakkude diferentseerumist mõjutav geeniekspressiooni regulaator. Ettevõte arendab ka PH-804, mis on suunatud supressiivsele immuunretseptorile TIGIT.
| Industry: | Biotechnology & Medical Research (NEC) |
257 Simarano Dr Ste 101
MARLBOROUGH
MASSACHUSETTS 01752-3070
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com